{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.2","upperLimit":"27.5","value":"17.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Overall survival is the time between the first day of treatment to the day of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"LMB-100 administered in cycles 1 and 2 + pembrolizumab administered in subsequent cycles.\n\nLMB-100 140mcg/kg Intravenous infusion (IVI), Days 1, 3, 5 in cycles 1, 2. Pembrolizumab 200mg IVI, every (Q) subsequent cycle on Day 1.\n\nLMB-100: Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles (i.e. RP2D was determined in a previous phase I trial).\n\nPembrolizumab: Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.","id":"OG000","title":"1/LMB- 100+Pembrolizumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time between the first day of treatment to the day of death, an average of 17 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}